OncoMatch/Clinical Trials/NCT07223047
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Is NCT07223047 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for advanced solid malignancies.
Treatment: BMS-986523 · Gemcitabine · Nab-Paclitaxel · Cetuximab · Pembrolizumab — The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Pancreatic Cancer
Biomarker criteria
Required: PD-L1 (CD274) overexpression (≥50%)
Required: KRAS amplification
Required: KRAS mutation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Local Institution - 0009 · Baltimore, Maryland
- NEXT Oncology · San Antonio, Texas
- START Mountain Region · West Valley City, Utah
- NEXT Virginia · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify